XASXWFL
Market cap923kUSD
Jul 21, Last price
0.00AUD
Name
Wellfully Ltd
Chart & Performance
P/E
—
P/S
0.98
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
2m
-42.00%
Net income
-6m
L-21.24%
CFO
-2m
L-70.38%
Earnings
Apr 07, 2025
Profile
Wellfully Limited, together with its subsidiaries, focuses on the development and commercialization of Dermaportation and ETP transdermal drug delivery technologies. It operates in two segments, Dermaportation Drug Delivery Technology and Devices. The company is also involved in the industrialization and supply-chain support for its existing product ranges; and sale and marketing of its own brands REDUIT and SWISSWELL, as well as third-party collaborations. It serves the pharmaceutical, cosmetic and skincare, and consumer healthcare sectors. The company was formerly known as OBJ Limited and changed its name to Wellfully Limited in September 2020. Wellfully Limited was incorporated in 1992 and is based in Leederville, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | 2015‑06 | |
| Income | |||||||||
Revenues | 1,508 -42.00% | 2,600 461.56% | |||||||
Cost of revenue | 5,163 | 8,173 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (3,656) | (5,573) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | (3,656) | (5,573) | |||||||
Net income | (6,355) -21.24% | (8,068) 26.12% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 3,152 | 5,826 | |||||||
BB yield | -283.21% | -46.88% | |||||||
| Debt | |||||||||
Debt current | 224 | 261 | |||||||
Long-term debt | 221 | 434 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | (46) | ||||||||
Net debt | 175 | 377 | |||||||
| Cash flow | |||||||||
Cash from operating activities | (2,443) | (8,249) | |||||||
CAPEX | (107) | (32) | |||||||
Cash from investing activities | (107) | (32) | |||||||
Cash from financing activities | 2,991 | 5,656 | |||||||
FCF | (1,628) | (5,795) | |||||||
| Balance | |||||||||
Cash | 270 | 318 | |||||||
Long term investments | |||||||||
Excess cash | 194 | 188 | |||||||
Stockholders' equity | (1,710) | (146) | |||||||
Invested Capital | 312 | 1,151 | |||||||
ROIC | |||||||||
ROCE | 261.40% | ||||||||
| EV | |||||||||
Common stock shares outstanding | 371,021 | 238,999 | |||||||
Price | 0.00 -94.23% | 0.05 4.00% | |||||||
Market cap | 1,113 -91.04% | 12,428 59.19% | |||||||
EV | 1,288 | 12,805 | |||||||
EBITDA | (3,542) | (5,401) | |||||||
EV/EBITDA | |||||||||
Interest | 56 | ||||||||
Interest/NOPBT | |||||||||